TrialMolecular oncology2021

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.

Brice Pastor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.